Dr Reddy’s has gained rights to a pair of proposed Stelara (ustekinumab) and Simponi (golimumab) biosimilars in multiple markets in south-east Asia, after striking an exclusive commercialization agreement with Bio-Thera Solutions.
Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera
Agreement Covers Stelara And Simponi Rivals In South-East Asia
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
